Back to Results

Aeon Biopharma Inc (AEON)

Aeon Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapies. Its lead product candidate, ABP-450 (prabotulinumtoxinA) injection, has completed a Phase 2 study for cervical dystonia and is also being evaluated in a Phase 2 program for chronic and episodic migraine. The company is additionally exploring ABP-450 for gastroparesis and post-traumatic stress disorder. Aeon Biopharma has license agreements with Daewoong Pharmaceutical Co., Ltd. and Viatris Inc. The company is based in Irvine, California, and its common stock is listed on the NYSE.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-AEON
$0.35
20.2% Upside
Undervalued
$6.70 2,210.3% Upside
—
Bargain
Weak
—
—
—
0.0%
August 18, 2026
-0.1x
-0.5x
—
7.603 M
4.011 M
25.6%
37.8%
-85.1
—
20.0%
Send a message
Valuation • Fair Value

Aeon Biopharma Inc (NYSE-AEON) Fair Value by Valuation Model

Compare the primary fair value estimate for Aeon Biopharma Inc (NYSE-AEON) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.35

Estimated upside of 20.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.35

Comparable-company valuation reference.

Analyst Price Target

$6.70 2,210.3% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Aeon Biopharma Inc (NYSE-AEON) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Aeon Biopharma Inc (NYSE-AEON)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-18.211 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Aeon Biopharma Inc (NYSE-AEON) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Aeon Biopharma Inc (NYSE-AEON)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-85.1

Lower score that deserves closer risk review.

FCF / Net Income

20.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Aeon Biopharma Inc (NYSE-AEON). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Aeon Biopharma Inc (NYSE-AEON)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 18, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Aeon Biopharma Inc (NYSE-AEON), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Aeon Biopharma Inc (NYSE-AEON) Stock Forecast & Technical Outlook

Review Aeon Biopharma Inc (NYSE-AEON) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Aeon Biopharma Inc (NYSE-AEON) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Aeon Biopharma Inc (NYSE-AEON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Aeon Biopharma Inc (NYSE-AEON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Aeon Biopharma Inc (NYSE-AEON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Aeon Biopharma Inc (NYSE-AEON) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Aeon Biopharma Inc (NYSE-AEON)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Aeon Biopharma Inc (NYSE-AEON) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Aeon Biopharma Inc (NYSE-AEON) Stock FAQ

Quick answers about Aeon Biopharma Inc (NYSE-AEON) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.35
Estimated upside 20.2%
Valuation Rating
Undervalued
Estimated upside of 20.2%
Analyst Target
$6.70 2,210.3% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Aeon Biopharma Inc (NYSE-AEON) is $0.35. This implies an estimated upside of 20.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 20.2% versus the current market price.

The available analyst price target for Aeon Biopharma Inc (NYSE-AEON) is $6.70 2,210.3% Upside.

The current financial health read for Aeon Biopharma Inc (NYSE-AEON) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Aeon Biopharma Inc (NYSE-AEON) is August 18, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Aeon Biopharma Inc (NYSE-AEON) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Aeon Biopharma Inc is 7.603 M.

The current enterprise value listed for Aeon Biopharma Inc is 4.011 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Aeon Biopharma Inc is NYSE-AEON, and the stock is listed on NYSE.

Aeon Biopharma Inc (NYSE-AEON) is listed on NYSE.

The current debt-to-total-capital ratio listed for Aeon Biopharma Inc is 25.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Aeon Biopharma Inc is 37.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NYSE View more

AbbVie Inc (ABBV) AbbVie Inc (ABBV)
Arcus Biosciences Inc (RCUS) Arcus Biosciences Inc (RCUS)
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Evommune Inc (EVMN) Evommune Inc (EVMN)
Emergent Biosolutions Inc (EBS) Emergent Biosolutions Inc (EBS)
Perspective Therapeutics Inc (CATX) Perspective Therapeutics Inc (CATX)
Lineage Cell Therapeutics Inc (LCTX) Lineage Cell Therapeutics Inc (LCTX)
Protalix Biotherapeutics Inc (PLX) Protalix Biotherapeutics Inc (PLX)
Armata Pharmaceuticals Inc (ARMP) Armata Pharmaceuticals Inc (ARMP)
Adc Therapeutics SA (ADCT) Adc Therapeutics SA (ADCT)
Pelthos Therapeutics Inc (PTHS) Pelthos Therapeutics Inc (PTHS)
Maia Biotechnology Inc (MAIA) Maia Biotechnology Inc (MAIA)
Annovis Bio Inc (ANVS) Annovis Bio Inc (ANVS)
OS Therapies Inc (OSTX) OS Therapies Inc (OSTX)
NanoViricides Inc (NNVC) NanoViricides Inc (NNVC)
Serina Therapeutics Inc (SER) Serina Therapeutics Inc (SER)
Apimeds Pharma US Ltd (APUS) Apimeds Pharma US Ltd (APUS)
Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM)
CEL-SCI Corp (CVM) CEL-SCI Corp (CVM)
Theriva Biologics Inc (TOVX) Theriva Biologics Inc (TOVX)
Regentis Biomaterials Ltd (RGNT) Regentis Biomaterials Ltd (RGNT)
Can Fite Biopharma Ltd ADR (CANF) Can Fite Biopharma Ltd ADR (CANF)
Kairos Pharma Ltd (KAPA) Kairos Pharma Ltd (KAPA)
AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM)